Pharmaceutical Development Group (PDG) provides pharmaceutical regulatory consulting to firms located around the world.
The company offers a one-stop-shop for US Food and Drug Administration (FDA) new drug application (NDA) compilation and submission, design and execution of toxicology and clinical programmes (Phases I-IV), sourcing and oversight of third party vendors including raw material suppliers, contract laboratories, contract research organisations (CRO), contract manufacturing organisations (CMO), and pre-approval inspections of all facilities.
FDA regulatory consultants for pharmaceutical development
Having facilitated hundreds of FDA pre-submission meetings and regulatory submissions for its clients, PDG knows how to determine and navigate the best regulatory pathway for your drug development project.
From submitting a Citizen Petition to changing a monograph or submitting a 505(b)(2) to repurpose a discontinued drug efficacy study implementation (DESI) drug, through priority review and accelerated approval of a new chemical entity, PDG has the expertise to see your project through.
PDG seeks to know the answers before asking FDA the questions
While this is never entirely possible, the model characterises the extent PDG prepares its submissions, and clients for FDA meetings.
The company’s approach to determining and illustrating risks and benefits integrates products, patient populations, and disease states with toxicology, pharmacokinetics, pharmacodynamics, clinical, statistical, epidemiology, CMC, labelling, and pharmacovigilance concerns.
PDG facilitates innovation, prolongs product lifecycles, evades generic competition, supplements dwindling pipelines, and differentiates or repurposes existing drug products.
As a regulatory strategist and pharmaceutical consultant, PDG understands that improvements in safety, efficacy, bioavailability, patient compliance, and convenience are viewed favourably by the FDA, as well as the marketplace.
The company knows through first-hand drug development experience how to help you develop novel formulations. It can also help you devise orphan, combination, or reformulation-based product development and other repositioning strategies that have the potential of yielding high returns on investment (ROI).
Typical of our services, but not entirely inclusive are the following:
- Pre-Investigational new drug (IND) / End of Phase II / Pre-NDA requests, briefing packages and facilitation
- IND / Special protocol assessment (SPA)
- Design of first-in-human through Phase IV studies
- NDA compilation and submission
- Mock FDA audits
- Postmarketing safety surveillance – signal detection
- Periodic reporting (PADERs/PSURs)
- Literature reviews
- Labelling currency
- Pharmaceutical consultants for complex issues and emergencies
The optimal time to engage a consultant such as PDG is in advance of meeting with FDA. However, PDG will engage at whatever point we are called upon, including regulatory emergencies such as those caused by unplanned audits or unanticipated inspection results.
PSG is ready to deploy for its clients 24/7 in all time-zones, including travelling to your facility when needed.
